Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 0.47 |
| ▸ | AKT1 | P31749 | 5/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | PHLPP1 | O60346 | 2/20 | 0.42 |
| ▸ | ILK | Q13418 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20822181 | 0.83 | ALOX5 (0.41) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL5772491 | 0.82 | AKT1 (0.64) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL5441388 | 0.81 | AKT1 (0.65) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL29393858 | 0.81 | AKT1 (0.65) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL3270839 | 0.81 | AKT1 (0.65) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL407517 | 0.81 | AKT1 (0.65) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL20819458 | 0.80 | AKT1 (0.42) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL20819459 | 0.80 | AKT1 (0.42) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL4779257 | 0.79 | ALOX5 (0.51) | ALOX5NR1I2PPARGPPARA | |
| SCHEMBL4780480 | 0.79 | ALOX5 (0.51) | ALOX5AKT1PDPK1PHLPP1ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015183984-A2 | THERAPEUTIC COMPOSITIONS INCLUDING TOCOPHEROL AND USES THEREOF | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-12-03 | — | — | WO | disclosed |
| EP-1912654-A4 | METHODS FOR SELECTIVELY TREATING COX-2 MEDIATED DISORDERS BY ADMINISTERING GAMMA-TOCOPHEROL | MERIAL LTD (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1912654-A2 | METHODS FOR SELECTIVELY TREATING COX-2 MEDIATED DISORDERS BY ADMINISTERING GAMMA-TOCOPHEROL | Merial Limited (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070015822-A1 | Methods for selectively treating COX-2 mediated disorders by administering gamma-tocopherol | MERIAL LIMITED | 2007-01-18 | — | — | US | disclosed |
| WO-2002047680-A2 | USE OF TOCOPHEROL, METABOLITES OR DERIVATIVES THEREOF OR FLAVONOID METABOLITES OR DERIVATIVES THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TISSUE ISCHEMIA | GALILEO LABORATORIES, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
| US-20010031782-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J (US) | 2001-10-18 | — | — | US | disclosed |
| EP-1140065-A1 | USE OF GAMMA-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-ALPHA IN THE TREATMENT OF DISEASE | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6242479-B1 | ADMINISTERING ORALLY OR PARENTALLY TO PREVENT CARDIOVASCULAR, NERVOUS SYSTEM, OR BRAIN DISORDERS; ANTIOXIDANTS, ANTICOAGULANTS, HYPOTENSIVE AGENTS; ATHEROSCLEROSIS | LOMA LINDA UNIVERSITY MEDICAL CENTER | 2001-06-05 | — | — | US | disclosed |
| US-6150402-A | Natriuretic compounds | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2000-11-21 | — | — | US | disclosed |
| US-6083982-A | STIMULATING SODIUM EXCRETION IN THE URINE OF A MAMMAL COMPRISING ADMINISTERING TO THE MAMMAL A ALKOXYALKYL OR HYDROXY ALKYL SUBSTITUTED PHENOLIC COMPOUND | LOMA LINDA UNIVERSITY MEDICAL (US) | 2000-07-04 | — | — | US | disclosed |
| WO-2000035444-A1 | USE OF η-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-α IN THE TREATMENT OF DISEASE | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2000-06-22 | — | — | WO | disclosed |
| US-6048891-A | ADMINISTERING MIXTURES WITH 6-HYDROXY-2,7,8-TRIMETHYL-CHROMAN-2-PROPANOIC ACID FOR TREATMENT OF CARDIOVASCULAR AND KIDNEY DISORDERS | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0792270-A1 | NATRIURETIC CYCLIC COMPOUNDS | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996005191-A1 | NATRIURETIC CYCLIC COMPOUNDS | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | ALOX5 150/4885AKT1 3368/4885PDPK1 4164/4885 |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | ALOX5 150/4885AKT1 3368/4885PDPK1 4164/4885 |
| US-20010031782-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, LPO | ALOX5 112/4885AKT1 3599/4885PDPK1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.